On the other hand, as PLCG2 has been associated with myeloid differentiation, it is also likely that the acquisition of our specific point mutation in non responder MDS patients could result in an impaired hematopoietic differentiation that leads to a stable disease or AML progression. This evidence concerns the gene PLCG2 and acute myeloid leukemia.